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Abstract
The cohesin complex has recently been shown to be a key regulator of eukaryotic gene expression, although
the mechanisms by which it exerts its effects are poorly understood. We have undertaken a genome-wide
analysis of DNA methylation in cohesin-deficient cell lines from probands with Cornelia de Lange syndrome
(CdLS). Heterozygous mutations in NIPBL, SMC1A and SMC3 genes account for ∼65% of individuals with
CdLS. SMC1A and SMC3 are subunits of the cohesin complex that controls sister chromatid cohesion,
whereas NIPBL facilitates cohesin loading and unloading. We have examined the methylation status of 27 578
CpG dinucleotides in 72 CdLS and control samples. We have documented the DNA methylation pattern in
human lymphoblastoid cell lines (LCLs) as well as identified specific differential DNA methylation in CdLS.
Subgroups of CdLS probands and controls can be classified using selected CpG loci. The X chromosome was
also found to have a unique DNA methylation pattern in CdLS. Cohesin preferentially binds to hypo-
methylated DNA in control LCLs, whereas the differential DNA methylation alters cohesin binding in CdLS.
Our results suggest that in addition to DNA methylation multiple mechanisms may be involved in
transcriptional regulation in human cells and in the resultant gene misexpression in CdLS.
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ABSTRACT
The cohesin complex has recently been shown to be
a key regulator of eukaryotic gene expression,
although the mechanisms by which it exerts its
effects are poorly understood. We have undertaken
a genome-wide analysis of DNA methylation in
cohesin-deficient cell lines from probands with
Cornelia de Lange syndrome (CdLS). Heterozygous
mutations in NIPBL, SMC1A and SMC3 genes
account for 65% of individuals with CdLS.
SMC1A and SMC3 are subunits of the cohesin
complex that controls sister chromatid cohesion,
whereas NIPBL facilitates cohesin loading and un-
loading. We have examined the methylation status
of 27 578 CpG dinucleotides in 72 CdLS and control
samples. We have documented the DNAmethylation
pattern in human lymphoblastoid cell lines (LCLs) as
well as identified specific differential DNA methyla-
tion in CdLS. Subgroups of CdLS probands and
controls can be classified using selected CpG loci.
The X chromosome was also found to have a unique
DNA methylation pattern in CdLS. Cohesin preferen-
tially binds to hypo-methylated DNA in control LCLs,
whereas the differential DNA methylation alters
cohesin binding in CdLS. Our results suggest that
in addition to DNA methylation multiple mechanisms
may be involved in transcriptional regulation in
human cells and in the resultant gene misexpression
in CdLS.
INTRODUCTION
Vertebrate gene expression is tightly regulated at several
levels which are mechanistically linked to each other (1).
DNA methylation, histone modiﬁcation and chromatin
remodeling are the most well-recognized and closely
interwoven epigenetic events (2). Epigenetic regulation
during development may occur very early during embryo-
genesis, driving the formation of diﬀerent organ systems
(3). DNA methylation is maintained by methyltransferase
DNMT1 in both mitosis and meiosis, and is considered
the most stable epigenetic mark (4).
In mammals, DNA methylation predominantly
occurs at CpG dinucleotides by covalent addition of a
methyl group to position 5 of the cytosine ring, creating
5-methylcytosine. CpG dinucleotides are under-
represented in the human genome with a frequency of
2–5% as compared to the GC content (5). CpG dinucleo-
tides are not equally distributed throughout the human
genome; instead, they occur in clusters of large repetitive
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sequences [such as ribisomal DNA (rDNA), satellite se-
quences or centromeric repeats] or in short CG-rich DNA
stretches, known as CpG islands (CGIs) (6). Dinucleotide
clusters of CpGs or ‘CpG islands’ are present in the
promoter and exonic regions of 40–70% of mammalian
genes and these clusters are usually unmethylated (7,8). By
contrast, other regions of the mammalian genome contain
less CpG dinucleotides and the majority (75%) of these
sparsely located CpG dinucleotides are largely methylated
(9). A large number of experiments have shown that
methylation of promoter CpG islands plays an important
role in gene expression, genomic imprinting,
X-chromosome inactivation, genomic instability, embry-
onic development and carcinogenesis (10,11).
Four DNA methyltransferases (DNMTs) (DNMT1,
DNMT2, DNMT3A and DNMT3B) and one DNMT-
related protein (DNMT3L) have been identiﬁed (12).
DNMT1 acts as a maintenance methyltransferase,
whereas DNMT2 may be an RNA methyltransferase,
and DNMT3a and DNMT3b are de novo methyl-
transferases targeting unmethylated DNA. All DNMTs
are essential for embryonic viability with homozygous
mutant mice dying early in development (13). MBD1-4
proteins or methyl CpG-binding proteins (MeCP2) recog-
nize and bind to methylated DNA. They recruit transcrip-
tional corepressors such as histone-deacetylating
complexes and polycomb group (PcG) proteins, associate
with chromatin-remodeling complexes and attract
chromodomain-binding proteins (13).
DNAmethylation and chromatin structure are strikingly
altered in many pathological situations, particularly in
cancers and various mental retardation syndromes.
Altered levels of the methyl donor folate and homocysteine
have been repeatedly linked to these disorders.
Disease-associated changes in epigenetic modiﬁcations
can be classiﬁed into changes in genes that are epigenetically
regulated and in genes that are part of the molecular ma-
chinery establishing and propagating the epigenetic modi-
ﬁcations through the development and cell divisions.
Aberrant methylation patterns have been reported in
various neurodevelopmental disorders, including X-linked
a-thalassemia and mental retardation (ATRX), Fragile X,
and immune deﬁciency, centromeric instability and facial
abnormalities (ICF) (14). Interestingly, the ATRX gene is
misexpressed in CdLS [+1.2, false discovery rate (FDR) =
0.07] and the disorder ATRX presents defective sister chro-
matid cohesion and is considered as one of the
‘cohesinopathies’ (15).
Cornelia de Lange syndrome (CdLS, OMIM#122470,
300590, 610759) is the ﬁrst identiﬁed ‘cohesinopathy’
which is a heterogeneous dominantly inherited develop-
mental disorder with multiple-organ system involvement
(16–19). The majority of CdLS probands were found to
have heterozygous mutations in the NIPBL gene, whereas
a small percentage have mutations in the SMC1A and
SMC3 genes. SMC1A and SMC3 are core components
of the cohesin complex which controls sister chromatid
cohesion during S phase, while NIPBL facilitates cohesin
loading and unloading (20,21). In addition to cohesin and
NIPBL’s canonical role in regulating sister chromatid
cohesion, they have also been implicated as key regulators
of gene expression over long distances (22,23), and have
been shown to preferentially associate to actively
transcribed genes and colocalize with RNA polymerase
II in Drosophila (24). In humans, cohesin colocalizes
with CTCF and regulates gene expression at the imprint-
ing IGF2/H19 locus (25). Moreover, we recently per-
formed a genome-wide transcription and cohesin-binding
study on CdLS cell lines and identiﬁed a CdLS-speciﬁc
expression proﬁle from NIPBL and cohesin mutant indi-
viduals. Our data also suggest that cohesin preferentially
binds to transcription start sites (TSSs) and tightly correl-
ates to transcriptional activation in humans. Loss of
cohesin binding occurs in CdLS and correlates to
dysregulated gene expression (26). We undertook a
genome-wide DNA methylation analysis on cell lines
from probands with CdLS for the following reasons:
First, the colocalization of CTCF and cohesin suggests
possible functional overlap between these two proteins.
A growing body of evidence suggests that CTCF is
involved in regulating DNA methylation in vertebrates
(14), and it binds to diverse DNA sequences including
most imprinting center regions and many CpG islands.
CTCF’s binding to chromatin seems sensitive to DNA
methylation, because it not only reads DNA-methylation
marks but also has a role in determining DNA methyla-
tion patterns. Second, NIPBL was reported to be involved
in chromatin remodeling by direct association with HP1,
linking NIPBL to multiple enzymes and protein factors
that determine the histone modiﬁcation patterns that
tightly correlate with DNA methylation status (27,28).
Third, a qualitative analysis of cohesin binding peaks in
control and CdLS cells using data obtained from our
previous chromatin immunoprecipitation (ChIP)–chip
assay (26) has revealed 6.85% of cohesin peaks overlap
CpG islands, while 7.77% of the lost peaks in CdLS
overlap CpG islands, hence CpG islands are
overrepresented by 6.35% (P= 0.0018) among cohesin
peaks that are lost in NIPBL mutant CdLS cells.
Fourth, we have identiﬁed diﬀerentially expressed genes
in CdLS from our previous genome-wide studies (using
a relatively loosened cutoﬀ of FDR< 0.2), multiple of
which are critical in DNA methylation. Of these, there
are several proteins directly involved in DNA methyla-
tion, such as the de novo DNA methyltransferase
DNMT1 (1.11, FDR=0.15), the universal
methyl-binding domain proteins MBD1 (1.23,
FDR=0.02) and MeCP2 (+1.11, FDR=0.06). In
addition, PcG proteins which form the polycomb repres-
sive complexes 1 and 2 (PRC1 and PRC2) are also
dysregulated in CdLS. For example, CBX7 (+1.2,
FDR=0.13) and BMI1(+1.36, FDR=0.02) in PRC1,
EZH2 (1.2, FDR=0.05) and SUZ12 (1.13,
FDR=0.199) in PRC2. Of note, Enhancer of Zeste
homolog 2 (EZH2) was suggested to serve as a recruitment
platform for DNA methyltransferases because it interacts
with methyltransferases (DNMTs) and associates with
DNMT activity in vivo (29). Another example is
GADD45A (+1.54, FDR=0.057) ectopic expression of
which leads to the reduction in methylation at both
speciﬁc gene loci and the total cellular 5-methylcytosine
content (30). Fifth, SmcHD1-a SMC hinge domain
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containing protein, maintains hypermethylation on the
inactivated X chromosome in mice (31); and a second
SMC-like protein-DMS3 mediates RNA-directed DNA
methylation (RdDM) in plants (32), functional identiﬁca-
tion of these two proteins therefore links cohesin to DNA
methylation. Sixth, ‘genomic neighborhood diseases’ have
recently been proposed (33), and are composed of genes
that are located in the same chromatin domain, are
co-expressed and communicate through three dimensional
structures. Dysregulated epigenetic events such as DNA
methylation are tightly involved in gene mis-expression
and the onset of these diseases. It is not known whether
mutations in NIPBL or cohesin might be able to alter
global DNA methylation and aﬀect genomic organization,
which may contribute to transcriptional dysregulation
in CdLS.
Very little is known about epigenetic regulation by
cohesin. Similarly, the role of epigenetic modulation in
CdLS and the majority of other human developmental
disorders are poorly characterized. To date, there has
been no global assessment of overall DNA methylation
in cohesin or NIPBL mutant human cells. We applied a
comprehensive DNA methylation proﬁling approach to
assess the epigenetic state in CdLS. We asked whether
these mutant cells diﬀered from healthy controls in
terms of DNA methylation. We used an array-based
method to quantitatively measure the methylation levels
of 27 578 CpG sites in the regulatory regions of 14 495
genes in the human genome. We have identiﬁed diﬀeren-
tial methylation patterns in CdLS probands and also
provided an integrative whole-genome view on DNA
methylation, gene expression and cohesin binding in
CdLS. We suggest CdLS has its own epigenetic signature
that is formed in the early stage of embryonic develop-
ment, which likely contributes to its clinical features.
MATERIALS AND METHODS
Sample collection
Sixty-three lymphoblastoid cell lines (LCLs) from 39
CdLS probands, two Roberts syndrome (RBS) probands
and 22 gender- and race-matched healthy controls were
tested. In addition, triplicates of one universally
methylated DNA control (Zymo Research) and tripli-
cates of each of two universally unmethylated DNA
controls were also included (CHEMICON). All the
tested CdLS probands have identiﬁed gene mutations
and well-documented clinical features, including 22
severely aﬀected probands with NIPBL mutations,
eight mildly aﬀected probands with NIPBL mutations,
eight mildly aﬀected probands with SMC1A mutations
and one mildly aﬀected proband with an SMC3
mutation. These samples include most of the individuals
studied in our previous gene expression project (26). All
human subjects participating in this study were enrolled
under an institutional review board-approved protocol of
informed consent at The Children’s Hospital of
Philadelphia and Misakaenosono Mutsumi
Developmental, Medical, and Welfare Center. All
subjects were evaluated by one or more experienced clin-
icians. Gene mutations were conﬁrmed by sequencing.
Cell culture and DNA isolation
LCLs were grown uniformly in RPMI 1640 with 20% fetal
bovine serum (FBS), 100U penicillin/ml, 100 mg strepto-
mycin/ml sulfate and 1% L-glutamine as described previ-
ously. All 63 cell lines were grown anonymously and
processed randomly. Genomic DNA was isolated from
LCLs following the manufacturer’s instruction (Gentra
Systems). The ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA) were used to check DNA
quality and quantity, respectively.
Bisulﬁte treatment of DNA samples
Prior to hybridization, bisulﬁte conversion of DNA
samples was performed using the EZ DNA methylation
kit (Zymo Research). Five-hundred nanograms DNA
were used; a thermocycling program with a short denatur-
ation step was included for bisulﬁte conversion (16 cycles
of 95C for 30 s followed by 50C for 1 h).
Methylation assays by Inﬁnium HumanMethylation27
BeadChip hybridization
After bisulﬁte treatment, each sample was whole-genome
ampliﬁed (WGA) and enzymatically fragmented, and
then applied to the BeadChips using Illumina-supplied
reagents and conditions at Genomic Facility at the the
Wistar Institute. HumanMethylation27 DNA Analysis
BeadChip (Illumina), which carries 27 578 highly inform-
ative CpG sites derived from the well-annotated NCBI
CCDS database (Genome Build 36) and spans more
than 14 495 genes, was used for this experiment.
Allele-speciﬁc primer annealing was followed by
single-base extension using DNP- and Biotin-labeled
ddNTPs. After extension, the array was ﬂuorescently
stained, scanned and the intensities of the unmethylated
and methylated bead types were measured by a BeadArray
Reader (34). Each methylation data point was represented
by ﬂuorescent signals from the M (methylated) and U
(unmethylated) alleles and was recorded via a
Methylation Module in BeadStudio software. DNA
methylation values were described as beta () values
which computed from the two alleles: =M/(U+M).
The -value therefore reﬂects the fractional methylation
level of each CpG site. DNA methylation -values are
continuous variables between 0 and 1, representing the
ratio of the intensity of the methylated bead type to the
combined locus intensity. We quantiﬁed methylation level
using -value, and performed the statistic analysis based
on the value of Log2[ /(1 – )] for more linearized data.
We arbitrarily deﬁned CpGs with Log2[/(1 – )]> 0 [also
equals to > 0.5 (50% of reads)] as hyper-methylated,
CpGs with Log2[b/(1 – )]<2 [also equals to < 0.2
(20% of reads)] as hypo-methylated, and CpGs with 2
<Log2[/(1 – )]< 0 as medium methylated.
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Statistical analysis
Data processing and statistical analyses were preformed
within R statistical environment (www.r-project.org); all
CpG sites were included in the analysis. Array data from
the methylated and unmethylated alleles were ﬁrst pro-
cessed separately by LOESS normalization across 63
LCL samples (the three sets of triplicated artiﬁcially
methylated and unmethylated DNA controls were
excluded) and then put together to calculate -values.
Diﬀerential methylation between control–CdLS or male–
female groups was evaluated by a two-way analysis of
variance (ANOVA) model with disease status and
sample gender as the two tested factors. FDR was
estimated by a procedure that randomly shuﬄed the
sample labeling and repeated the ANOVA test 100 times.
Bisulﬁte sequencing validation
To validate the data obtained using the
HumanMethylation27 BeadChip, samples from four to
six healthy controls and four to six severely aﬀected
probands with NIPBL mutations were evaluated by
bisulﬁte sequencing (BS). The genomic addresses and
sequence information of each CpG dinucleotide on the
BeadChip were downloaded from the company’s
database (Illumina); ±200 bp surrounding the target
CpG of CAPN2 and LMO2 were retrieved from the
UCSC genome database (http://genome.ucsc.edu/) and
used as template sequence to design polymerase chain
reaction (PCR) primers. Genomic DNA (1 mg) was
bisulﬁte-converted and recovered as described above.
Primers were designed by Methyl Primer Express v1.0
software (Applied Biosystems) using default settings.
Primer sequences are available on request. Hot-start
touchdown PCR was done in 25 ml reaction containing
0.25mM dNTPs, 1 buﬀer, 0.4 mM forward and reverse
primers and 1U of ZymoTaqTM DNA Polymerase (Zymo
Research). The PCR conditions were as the following:
94C for 15min, then 14 cycles with a gradual decrease
of annealing temperature from 62C to 55C with 0.5C
reduction per cycle followed by 72C for 1min per cycle.
After that, ampliﬁcation was continued with 36 cycles of
94C for 30 s, 55C for 30 s and 72C for 1min, then ended
with 72C for 15–20min. PCR products were veriﬁed by
gel electrophoresis, 2 ul PCR product was subsequently
cloned into pGEM-T vector and transformed into
JM109 cells according to the manufacturer’s instruction
(Promega). Ten to twelve individual clones of each PCR
fragment were selected for sequencing using an ABI Prism
377 automatic sequencer (Applied Biosystems) with T7
primer. Sequencher and MacVector were used to align
obtained sequences with reference sequences from the
UCSC genome browser (http://genome.ucsc.edu/). C!T
changes at CpG sites were documented.
Aﬀymetrix expression array hybridization and ChIP
microarray analysis
All procedures were performed as describe in our previous
publication (26).
Online data mining
EpiGRAPH (http://epigraph.mpi-inf.mpg.de/
WebGRAPH/) is an online software to analyze genomic
and epigenomic features enriched in a group of given
DNA fragments (35–37). EpiGRAPH was used to
analyze DNA sequences harboring the diﬀerentially
methylated CpG sites in CdLS in terms of the speciﬁc
DNA sequence patterns, the overlap with speciﬁc
genomic regions (e.g. CpG islands, repetitive regions and
SNPs) and histone modiﬁcation makers. Galaxy
(http://galaxy.psu.edu/) was used to format downloaded
genomic sequences from the UCSC genome browser
(http://genome.ucsc.edu/). ClustalW2 (http://www.ebi.ac
.uk/Tools/clustalw2/index.html) was used to identify con-
sensus sequence around CpG sites whose methylation was
signiﬁcantly changed in CdLS.
Accession numbers
Genomic sequences reported in this manuscript have been
submitted to NCBI GEO (http://www.ncbi.nlm.nih
.gov/geo): methylation data are under accession number
GSE 18458, gene expression data are under accession
number GSE 12408 and ChIP–chip data are under acces-
sion number GSE 12603.
RESULTS
The overall whole-genome DNA methylation patterns in
human LCLs in healthy controls
Whole-genome DNA methylation studies were conducted
on 72 sodium bisulﬁte-converted DNA samples obtained
from 63 sample LCLs, two sets of triplicated artiﬁcially
de-methylated DNA controls and one set of triplicated
artiﬁcially fully methylated DNA controls. Inﬁnium
HumanMethylation27 BeadChip that carries 27 578 CpG
dinucleotides located within the promoter region of 14 495
unique genes in the human genome was used for hybrid-
ization. Hybridization signal and -value were examined
as described in ‘Material and Methods’ section, < 0.2
(20% of reads) was considered as low level of methylation,
while > 0.5 (50% of reads) was considered as high level
of methylation. Linearized Log2 [ /(1 – )] was used for
statistic analysis. Samples were selected from Caucasian
individuals and gender and age were closely matched.
The 63 experimental samples included 22 healthy
controls, 22 severely aﬀected CdLS probands with
NIPBL protein truncating mutations, eight mildly
aﬀected CdLS probands with NIPBL missense mutations,
eight mildly aﬀected CdLS probands with SMC1A muta-
tions, one mildly aﬀected proband with the SMC3
mutation and two RBS probands with homozygous mu-
tations in ESCO2 (Supplementary Table S1). After nor-
malization, the six replicated unmethylated and three
replicated methylated artiﬁcial DNA control samples
showed corresponding low and high -values, indicating
an eﬃcient bisulﬁte conversion of DNA samples
(Supplementary Figure S1). The methylation density
peaks of all of the 63 experimental samples have Log2
[/(1 – )] < 0 and overlap the peaks of the unmethylated
5660 Nucleic Acids Research, 2010, Vol. 38, No. 17
artiﬁcial controls, indicating that the DNA from human
LCLs is hypo-methylated globally (Supplementary
Figure S1). There are 26 486 CpG dinucleotides on the
human autosomes (chromosomes 1–22), the average
DNA methylation levels of these dinucleotides are highly
variable among the 22 control LCLs, but the majority of
them are hypo-methylated. Bimodal distribution of DNA
methylation was seen on all CpGs among the 22 controls,
suggesting two types of genomic contents may be
produced by DNA methylation. This bimodal distribution
further suggests that it may represent the overall
hypo-methylation of CpG sites inside CpG islands and
the overall hyper-methylation of CpG sites located
within the CpG poor genomic regions in human LCLs
(Supplementary Figure S1).
Identiﬁcation of CdLS speciﬁc DNA methylation
patterns in LCLs
Diﬀerential DNA methylation identiﬁed in CdLS
probands. Methylation levels of 26 486 probes on auto-
somes (chromosomes 1–22) were quantiﬁed by , after-
wards Log2 [/(1 – )] of each probe in each sample was
calculated and used for unsupervised principal component
analysis (PCA). Figure 1A depicts that the 22 severely
aﬀected CdLS probands with NIPBL protein truncating
mutations can be separated from the 22 healthy controls
solely based on DNA methylation levels on autosomes
except ﬁve healthy control samples. Control
‘AGS-222-S’, ‘27574’, ‘CDL-145-03S’, ‘27572-B’ and
‘95-3986-S’ are discordant to the rest of other samples in
control group. This unsupervised PCA result indicates
that the genome-wide DNA methylation proﬁle is signiﬁ-
cantly diﬀerent in CdLS as compared to healthy individ-
uals. Probes on X and Y were excluded due to the gender
eﬀect on DNA methylation.
In order to deﬁne the diﬀerentially methylated DNA
loci in CdLS, we performed a two-way ANOVA analysis
of the total 27 578 probes on the control group (22 indi-
viduals) and the severely aﬀected NIPBL mutant CdLS
group (22 individuals). There are 924 CpG sites (corres-
ponding to 902 cognate genes) diﬀerentially methylated in
CdLS with P< 0.01 (FDR=0.222), out of these 924 CpG
sites, methylation levels were decreased on 361 sites
(356 genes) and increased on 563 (546 genes) sites in
CdLS (Supplementary Table S2). We selected 152 diﬀer-
entially methylated CpG sites on the autosomes with
P< 0.001 (Supplementary Table S2) and further per-
formed clustering analysis on all of the 63 samples in
our cohort which are varied both clinically and
genotypically (Figure 1B). Samples from each subgroup
could be clustered together, although with a few outliers.
Control samples and severely aﬀected NIPBL mutant
CdLS probands are evidently separated from each other,
whereas mildly aﬀected CdLS probands stay in between.
Within the mildly aﬀected CdLS probands, individuals
with NIPBL mutations stay closer to the NIPBL mutant
subgroup that has severe manifestations, whereas CdLS
probands with other gene mutations (SMC1A and
SMC3) tend to cluster together and stay closer to
healthy controls. Interestingly, the two RBS probands
are clustered side by side with SMC1Amutant individuals.
RBS is an autosomal recessive genetic disorder due to
homozygous or compound heterozygous mutations in
the ESCO2 gene, ESCO2 has acetyltransferase activity
and is involved in the establishment of sister chromatid
cohesion.
The X chromosome has a unique DNA methylation pattern
in CdLS. We further separately analyzed the hypo-
methylated CpG sites (Log2[/(1)] <2) and
hyper-methylated CpG sites (Log2 [/(1 – )] >0) in
controls. In addition, autosomal and X-linked sites were
also analyzed separately (Supplementary Table S3). In
general, the average DNA methylation levels of all of
the hyper-methylated CpG sites and the X-linked
hypo-methylated CpG sites have been increased in
Figure 1. CdLS speciﬁc DNA methylation proﬁle revealed by unsuper-
vised and supervised classiﬁcation analysis. (A) Unsupervised principal
component analysis (PCA) of DNA methylation on 26 486 autosomal
CpG sites. Twenty-two severely aﬀected CdLS probands with NIPBL
mutations and 22 healthy controls are clearly separated into two groups
except ﬁve controls. Log2[/(1 – )] was calculated for each probe in
each sample. (B) Hierarchial clustering of 63 experimental samples
based on 152 diﬀerentially methylated autosomal CpG sites
(P< 0.001). Individuals with diﬀerent clinical presentations are
color-coded, the corresponding gene mutations are labeled inside the
brackets.
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CdLS, whereas the autosomal hypo-methylated CpG sites
remain unchanged (Figure 2A). Statistically, the average
methylation level (combining both females and males) of
X-linked hypo-methylated CpG sites has increased signiﬁ-
cantly in CdLS as compared to the increase of autosomal
hypo-methylated CpG sites (P=1.51E-08) (Figure 2A).
Since gender could play a major role aﬀecting DNA
methylation levels, we then repeated the above analysis
by analyzing female and male samples separately. We
saw more signiﬁcant methylation change of
hypo-methylated CpG sites on the X chromosome than
on the autosomes in CdLS females (P=3.5E-17).
Signiﬁcant increase in DNA methylation of
hypo-methylated CpG sites than that of hyper-methylated
CpG sites was also found on X chromosome in female
CdLS probands (P=1.2E-12) (Figure 2B). Surprisingly,
signiﬁcantly reduced methylation levels were found for the
above hypo-methylated CpG sites on the X chromosomes
in male CdLS probands (Figure 2B).
The correlation between the diﬀerential DNA methylation
and the dysregulated gene expression in CdLS
General correlation between DNA methylation and gene
expression in control human LCLs. The expression of
genes in LCLs and the methylation levels of their
associated CpG sites were ﬁrst examined in 22 control
samples. We took advantage of the whole-genome expres-
sion analysis from our previous study (26), in which we
have identiﬁed 10 378 out of 15 162 unique refSeq genes
expressed in LCLs using Aﬀymetrix HG_U133plus2.0
arrays. Each of these genes was mapped to one and only
one transcription starting site (TSS). CpG dinucleotides
were mapped to within ±1-kb regions surrounding TSSs
to obtain 22 351 TSS–CpG pairs from 12 081 unique genes
and 21 110 unique CpG sites. Consistent with the
well-documented literature, an inverse correlation
between DNA methylation and gene expression was also
found in LCLs in our study. DNA methylation suppresses
gene expression and the reduced methylation level correl-
ates to higher probability of gene expression (Figure 3A,
Supplementary Figure S2A). Figure 3A shows the percent-
age of expressed genes and the corresponding CpG methy-
lation levels. The overall percentage of genes expressed in
LCLs is 69.9% (8449/12 081), which indicates that 69.9%
of human genes are likely to be expressed in LCLs. While
the level of DNA methylation is increased, fewer genes are
expressed. Using (Log2 [/(1 – )]=0) as cutoﬀ, Fisher’s
exact test shows highly signiﬁcant interdependence
between gene expression and DNA methylation in the
promoter region (P=4.5E-315) (Figure 3A). The
elevated expression of a subgroup of genes that is
associated with hyper-methylation (Log2[/(1 – )]>0)
seems to be unexpected, suggesting mechanisms other
than DNA methylation are involved in their transcription-
al regulation; or in another word, DNA methylation alone
is not enough to downregulate gene expression in human
LCLs (Figure 3A, Supplementary Figure S2A). We
subdivided the 21 110 unique sites into two groups based
on the CpG island mapping information from the UCSC
genome browser (http://genome.ucsc.edu) as CpG sites
located within the CpG island (CGI sites) and outside
the CpG island (non-CGI sites). There was no linear cor-
relation between the level of DNA methylation and the
transcriptional activity of the cognate gene observed
for both CGI sites and non-CGI sites, which further
indicated the direct impact from DNA methylation
on gene expression might not be predominant
(Supplementary Figure S2B).
We also found that the relative location of the CpG site
to the TSS impacts the association between DNA methy-
lation and the expression of the downstream gene
(Figure 3B). While 44.5% (1224/2752) of the genes with
hyper-methylated CpG sites around their TSSs were ex-
pressed in LCLs, the closer the sites were located to the
TSSs, the less likely the genes were to be expressed. When
there was a hyper-methylated site located within ±50
bases around a TSS, the downstream gene had only a
27.6% (93/337) chance of being expressed. However,
such an eﬀect of the hypo-methylated sites was less
evident. The negative correlation between DNA methyla-
tion and gene expression is stronger on autosomes than on
the X chromosome (Supplementary Figure S2C). The
probability of genes to be expressed on autosomes and
the X chromosome is 82.3% and 61.4%, respectively
(P=6.0E-06) when there is a hypo-methylated site
around the TSS in female samples, and 36.8% and
44.5% (P=0.08) when there is a hyper-methylated site.
This observation suggests that the association between
DNA methylation and gene expression has diﬀerent mech-
anisms on autosomes and the X chromosome.
The correlation between diﬀerential DNA methylation and
altered gene expression in CdLS. As described earlier,
12 081 unique refSeq genes are associated with CpG sites
with DNA methylation information available from this
study. Out of these 12 801 genes, 8449 genes are expressed
in LCLs. We compared the expression level and the
methylation level for each of these 8449 genes between
22 controls and 22 severely aﬀected NIPBL mutant
CdLS probands, then we plotted the alteration of expres-
sion to the alteration of methylation for each gene. In
general, there is no strong evidence supporting that
global diﬀerential DNA methylation correlates to global
transcriptional dysregulation in CdLS (Figure 4). The
increased DNA methylation level correlates to the tran-
scription downregulation for only six genes in CdLS
(P=0.003), whereas the decreased DNA methylation
level correlates to transcriptional upregualtion for only
two genes but without statistic signiﬁcance (Figure 4,
Supplementary Table S4). There is no link seen between
the altered gene expression of the rest of 8441 genes and
the altered DNA methylation in CdLS (Figure 4). We
therefore conclude that the diﬀerential DNA methylation
may not directly contribute to the transcriptional
dysregulation in CdLS.
The correlation between the diﬀerential DNA methylation
and cohesin binding in CdLS
Cohesin preferentially binds to hypomethylated DNA in
control human LCLs. The average DNA methylation
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Figure 2. Box plots showing DNA methylation changes for hypo-methylated CpG sites on chromosome X are diﬀerent in CdLS. (A) DNA
methylation levels of X-linked hypo-methylated CpG sites have signiﬁcantly increased in CdLS as compared to autosomal hypo-methylated CpG
sites. Twenty-two controls and 22 severely aﬀected CdLS probands with NIPBL mutations were included. (B) DNA methylation levels of X-linked
hypo-methylated CpG sites have signiﬁcantly increased in female CdLS probands but decreased in male CdLS probands as compared with methy-
lation changes of the autosomal CpG sites. Twenty-two controls and 22 severely aﬀected CdLS probands with NIPBL mutations were included, and
females (11 controls and 11 probands) and males (11 controls and 11 probands) were analyzed separately. The label of Y-axis is deﬁned as
‘CdLS-Control’=Log2 (/1 – )CdLS – Log2 (/1 – )Control, indicating the alteration of methylation levels between CdLS and controls.
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level of 21 110 CpG sites associated to the above 12 081
genes in 22 controls were analyzed with Log2[/(1 – )].
Cohesin binding signal was obtained from our previous
ChIP–chip assay (26), re-analyzed quantitatively and
mapped to each of 21 110 CpG site. The majority
of cohesin signals were concentrated at chromatin
regions with a low level of DNA methylation which
is Log2[/(1 – )]< –2 (< 0.2), indicating that cohesin
preferentially binds to hypo-methylated chromatin;
meanwhile, an increased DNA methylation level prohibits
cohesin from binding to the chromatin (Supplementary
Figure S3A and B). From our previous study (26),
we have shown evidence that cohesin preferentially binds
to gene promoters especially at TSSs. We therefore
split the 12 081 genes into three groups according to the
methylation levels of the CpG sites at their TSSs, and
looked at cohesin binding intensities around promoters.
As described above, CpGs with Log2[/(1 – )]> 0 were
Figure 3. Correlation between the DNA methylation and the gene expression in human LCLs. (A) Increased level of DNA methylation correlates to
reduced gene expression. A total of 22 351 TSS–CpG pairs from 12 081 unique genes were analyzed. The broken line indicates that 8449 (69.9%) of
these genes were expressed in LCLs. (B) Location of the CpG sites impacts the association between DNA methylation and gene expression. Among
the genes having hyper-methylated CpG sites around their TSSs, the closer the CpG sites are located to TSS, the less possible the downstream gene is
expressed (red lines). This eﬀect is not obvious among genes with hypo-methylated CpG sites around their TSSs (green lines).
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deﬁned as hyper-methylated, while CpGs with Log2[/
(1 –)]< –2 were deﬁned as hypo-methylated, and CpGs
with 2 <Log2[/(1 – )]< 0 were deﬁned as medium
methylated. A similar cohesin-binding pattern was
identiﬁed for the 8128 genes with hypo-methylated CpGs
and the 2247 medium methylated CpGs. Cohesin prefer-
entially binds to the vicinity of their TSSs especially
around the core promoter region (from 200 bp to
+1bp) with each peak clearly seen (Figure 5). On the
contrary, very little cohesin binds to the 1706 genes
with hyper-methylated CpGs, and there is no quantitative
diﬀerence of cohesin binding to diﬀerent regions sur-
rounding the TSSs (Figure 5). Although cohesin binding
correlates to gene expression (26), we were not able to
identify a direct correlation between gene expression and
DNA methylation based on our above analyses. In com-
bination with our previous studies, these results suggest
the association between cohesin and promoters are
tightly correlated to gene expression, but DNA methyla-
tion may only be one of several upstream events that aﬀect
cohesin binding. The transcriptional regulation does
not appear to solely depend on DNA methylation but
rather multiple mechanisms or pathways are likely func-
tioning together to control the expression of genes in
human LCLs.
Diﬀerential DNA methylation alters cohesin binding in
CdLS. In addition to respectively examining genes with
hypo-methylated promoters and hyper-methylated pro-
moters in CdLS, we also wanted to examine whether the
X chromosome or autosome location of the CpG
dinucleotide will diﬀerently aﬀect the correlation
between DNA methylation and cohesin binding in
CdLS, hence only the female samples from the control
group and severely aﬀected NIPBL mutant CdLS individ-
uals were analyzed. For the genes with hypo-methylated
promoters, binding of cohesin is enriched around TSSs
regardless of whether they are located on autosomes
(6692 genes) or X chromosome (145 genes); however,
Figure 4. The change of DNA methylation does not generally aﬀect gene expression in CdLS. The 8449 genes that were expressed in LCLs were
examined in 22 controls and 22 severely aﬀected probands. The increased methylation shows a signiﬁcant suppression eﬀect on transcription for only
six genes in CdLS with P=0.003 in Fisher’s test. The decreased DNA methylation reveals no signiﬁcant correlation with transcriptional
upregulation in CdLS. Y-axis represents the gene expression changes in CdLS calculated with signal intensity on expression arrays; x-axis represents
the methylation alteration in CdLS using Log2 (/1 – ). The 0.5 cutoﬀ value was set up arbitrarily.
Figure 5. Cohesin preferentially binds to CpG sites at promoter
regions with low levels of DNA methylation. Very little cohesin
binds to hyper-methylated promoters regardless of the distance
to TSSs. Log2(/1 – )> 0 was deﬁned as hyper-methylation, Log2(/
1–)<2 was deﬁned as hypo-methylation, 2<Log2(/1–)< 0 was
deﬁned as medium methylation. Cohesin binding signal was quantiﬁed
from previous ChIP–chip study and log-transformed before the
analysis.
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less cohesin binds to the X chromosome than to auto-
somes and the peak shifts upstream of the TSS. In
CdLS, the amount of both autosomal and X chromosome
bound cohesin has decreased, although a smaller peak
remains in a narrowed region surrounding the TSS
(Figure 6A). For the genes with hyper-methylated pro-
moters, the amount of cohesin bound is quite low for
both autosomal and X-linked genes (1640 and 129, re-
spectively) (Figure 6B), and cohesin binding is equally
distributed along ±1.5-kb region of TSSs with no
obvious peak seen at TSSs. More cohesin is associated
with the X chromosome than with the autosomes in
controls but this tendency was reversed in CdLS which
shows less cohesin associated with the X chromosome
than with autosomes (Figure 6B). A slightly reduced
amount of cohesin binds to the X chromosome in CdLS,
but there is little change in cohesin binding to autosomal
genes in CdLS (Figure 6B). In summary, cohesin binding
has changed remarkably at hypo-methylated promoters in
CdLS, with unknown mechanisms in addition to DNA
methylation likely involved in regulating cohesin binding
to X-linked and hyper-methylated promoters.
BS validation for microarray results and evidence of
varied DNA methylation in control LCLs
Bisulﬁte conversion and sequencing described by Susan
Clark (38) has always been considered the gold standard
by which to measure CpG methylation. We selected
two genes, LMO2 and CAPN2, which demonstrated dif-
ferential methylation between CdLS and control cells, for
BS validation. In our previous studies (26), these two
Figure 6. Reduced cohesin binding at hypo-methylated promoters in CdLS with minimal changes for hyper-methylated promoters. (A) Cohesin
binding to genes with hypo-methyated promoters is reduced in CdLS, and less cohesin binds to promoters on the X chromosome than on autosomes;
6692 of such genes are on autosomes, while 145 are on the X chromosome. (B) Less cohesin binds to genes with hyper-methylated promoters in both
controls and probands; however, more cohesin binds to X-linked promoters than to autosomal promoters in controls and this X-linked cohesin
binding is reduced in CdLS. Log2(/1 – )<2 was deﬁned as hypo-methylation and Log2(/1 – )> 0 was deﬁned as hyper-methylation. Cohesin
signal was quantiﬁed and log-transformed before the analysis. Only 11 female samples from controls and 11 female samples from severely aﬀected
CdLS probands were analyzed.
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genes showed reduced transcription and loss of cohesin
binding to TSSs in CdLS cells. There is a big CpG
island embedded at the CAPN2 promoter region; two
probes, cg01566170 and cg14972271 on the
HumanMethylation27 array, were located 455 bp and
465 bp upstream of the TSS of CAPN2, respectively.
The 252-bp fragment (chr1:221,966,278-221,966,529)
ampliﬁed by primers CAPN2 329/330 covers these
two probe CpG sites in addition to seven other CpG di-
nucleotides included in this fragment. DNA isolated from
four controls and four severely aﬀected CdLS probands
with NIPBL mutations tested on methylation arrays
above were tested again by BS. Ten to twelve clones
were sequenced for each sample. Figure 7 shows the
increased number of 5-methylcytosine at CpG sites in
CdLS probands, indicating elevated DNA methylation
levels in this chromatin region at the CAPN2 promoter
which is consistent with the methylation microarray
ﬁndings. In addition, the BS result from control samples
also illustrated varied levels of DNA methylation in the
healthy population. Sample 11 obviously has much higher
methylation level than sample 46 and 48, although, on
average, 48.8% of CpGs in control and 80.3% in CdLS
are methylated. A second promoter region, the promoter
of the LMO2 gene, was also tested by BS in six control
and six CdLS individuals. A 358-bp fragment that is
located at the LMO2 promoter region was ampliﬁed by
primers LMO2 337/338. This examined fragment is
located on chr11:33,870,140-33,870,497 surrounding
probe cg11822932 on the HumanMethylation27 array,
which is 120 bp upstream of the TSS of LMO2. The
LMO2 promoter is very CpG poor and harbors no
region that meets the criteria of the ‘CpG island’. There
are only three CpG dinucleotides in this tested region
including the probe CpG. We could demonstrate similar
methylation changes at the LMO2 locus as demonstrated
by the array study (Supplementary Figure S4). In conclu-
sion, a consistent methylation pattern was obtained from
both BS and HumanMethylation27 analysis.
Speciﬁc histone modiﬁcations and repetitive sequences are
involved in the diﬀerential methylation in CdLS by
EpiGRAPH analysis
EpiGRAPH (http://epigraph.mpi-inf.mpg.de/
WebGRAPH/) is an online software to analyze genomic
and epigenomic features that are enriched in given DNA
fragments (35–37). As described above, we have identiﬁed
924 CpG sites correlated to 902 genes that are diﬀerential-
ly methylated in CdLS (P< 0.01), out of which the methy-
lation level of 361 CpGs (356 genes) are decreased and the
methylation level of 563 CpGs (546 genes) are increased.
The EpiGRAPH web service was used to analyze DNA
features enriched in regions with diﬀerential methylation
in CdLS. One kilobase DNA sequence (±500 bp) sur-
rounding each of the 924 CpG dinucleotides was identiﬁed
and downloaded from the UCSC genome browser (http://
genome.ucsc.edu/), processed in Galaxy (http://galaxy
.psu.edu/) and uploaded to EpiGRAPH to identify
overrepresented genomic or epigenomic features by
comparing the 361 sequences harboring hyper-methylated
CpGs and the 563 sequences harboring the hypo-
methylated CpGs in CdLS. We chose a size of 1000 bp
for the analyses because in normal tissues the extended
distance of DNA methylation is generally shorter than
1000 bp (13). Signiﬁcantly distinct histone modiﬁcations
were found in chromatin regions with both diﬀerential
DNA hypo-methylation and hyper-methylation,
indicating a tight correlation between the alteration of
DNA methylation and the diverse chromatin structure
in CdLS (Table 1, Supplementary Table S5). The ﬁnding
that repetitive sequences are enriched in chromatin regions
harboring diﬀerentially methylated CpG sites is very inter-
esting because cohesin binding is dysregulated in CdLS
and the association between cohesin and repetitive
sequences has been suggested to be involved in multiple
biological roles (15). ClustalW2 (http://www.ebi.ac
.uk/Tools/clustalw2/index.html) was further used to look
for consensus sequences covering the diﬀerentially
Figure 7. Bisulﬁte sequencing of a 252-bp fragment that is located at the CAPN2 promoter region in four control and four CdLS samples. The
examined fragment is located on chr1:221,966,278-221,966,529 surrounding probes cg01566170 and cg14972271 on the HumanMethylation27 array,
which are 455 bp and 465 bp upstream of the TSS of CAPN2, respectively. There are nine CpG dinucleotides in this region. A solid block represents
the methylated ‘C’ allele that remains as ‘C’ after bisulﬁte conversion and an empty block represents the unmethylated ‘C’ allele that was converted
to ‘T’ after bisulﬁte treatment. Ten to twelve clones were selected for sequencing for each sample. Each row represents one sequenced clone and each
column represents one examined ‘CpG’ site. The arrows point to probes cg01566170 and cg14972271.
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methylated CpG sites; however, no consensus sequences
could be identiﬁed (data not shown).
DISCUSSION
CdLS is a dominant genetic disorder with multiple-organ
system abnormalities, including characteristic facial
features, limb defects, mental retardation, developmental
delay and gastrointestinal problems. Mutations in the
cohesin regulatory protein NIPBL and cohesin subunits
SMC1A and SMC3 account for 65% of conﬁdently
diagnosed probands, while the remaining 35% of
probands have no identiﬁable gene mutations (19). Prior
studies (19) have shown that CdLS probands with SMC3
and SMC1A mutations present with a milder clinical
picture than the classic form of CdLS typically associated
with protein truncating mutations in NIPBL. Since
NIPBL is a regulator of the cohesin complex and both
SMC3 and SMC1A are actual structural components of
the cohesin complex, the exact mechanisms by which mu-
tations in these proteins manifest their eﬀects on develop-
ment and gene regulation are likely to be quite diﬀerent.
The cohesin complex consists of four major subunits,
SMC1A, SMC3, RAD21 and STAG1/STAG2, forming
a ring structure holding sister chromatid together during
mitosis and meiosis (39). Additionally, cohesin has been
suggested to play pivotal roles in fundamental biological
events in humans such as gene expression (22,26),
double-strand DNA repair (40,41), genome instability
(42), carcinogenesis (43) and chromatin loop formation
(44). The co-localization of cohesin and CTCF in human
cells further suggests functional cooperation and overlap
may exist between these two proteins (25). Of note, muta-
tions in cohesin accessory factors such as NIPBL, ESCO2
and ATRX have also been identiﬁed in human develop-
mental disorders with similar but quite distinct clinical
presentations which are currently collectively named
‘cohesinopathies’ (15). The cohesinopathies provide
valuable experimental models with naturally occurring
mutations to study the biological functions of the
cohesin pathway in general and the speciﬁc proteins in
particular in human cells. Recently, the term ‘genomic
disorder’ was proposed to describe groups of developmen-
tal disorders or human maligancies in which epigenetic
mechanisms including DNA methylation play important
roles in the pathogenesis (33). It is not known whether
similar mechanisms could also be involved in CdLS.
We chose to use a seemingly phenotypically unrelated
tissue type, LCL, in this proof-of-principle study on a
human developmental disorder, CdLS, based on two con-
siderations: availability of the sample and goals of the
project. As opposed to primary ﬁbroblasts which repre-
sent a limited resource, has uncontrollable environmental
exposure (such as diet or medications), and has signiﬁcant
variation of growth and survival rate across diﬀerent
samples in culture, patient-derived LCLs for genome-wide
DNA methylation studies on human subjects has obvious
advantages including (i) easier growth under controlled
conditions to minimize the environmental inﬂuence on
DNA methylation, (ii) ease of identiﬁcation of suﬃcient
numbers of matched samples (gender, age, clinical mani-
festations, etc.) for valid statistical analysis that would be
much more diﬃcult using ﬁbroblasts (especially for groups
engaged in the study of rare human disorders) and (iii)
provides continually renewable and stable biomaterials
that ensure for sequential integrated genomic analyses.
Of note, GM12878, a well-circulated model LCL, has
been universally used in the HapMap, ENCODE, and
other major projects. Publicized DNA methylation data
generated for GM12878 on the same Illumina platform
demonstrated good correlation with our LCL samples
with r=0.947 when the low-quality measurements were
removed (Zhang et al., manuscript in preparation). In
addition, LCLs have been widely used as surrogates or
as cellular models to study epigenetic changes in neuro-
psychiatric illnesses such as autism, bipolar disorder,
schizophrenia and in central nervous system disorders
such as Parkinson disease (45). Genetic disorders, such
as ataxia telangiectasia (46) and Nijmegen breakage
syndrome, have also been investigated on patient derived
LCLs yielding valuable insights into the pathobiology of
these disorders (47).
Methylation and demethylation of regulatory sequences
in the genome are known to have profound eﬀects on
cellular behavior and fate. In this study, we have per-
formed genome-wide DNA methylation analysis in
CdLS using Illumina Methylation27 bead chip carrying
27 578 CpG dinucleotides that represents 14 495 cognate
genes in the human genome. The power of this array is
that a very large number of sites can be determined sim-
ultaneously, allowing highly reproducible global patterns
to be discovered. Both unsupervised PCA based on results
of all data from available CpG sites and the supervised
clustering signatures based on diﬀerentially methylated
autosomal CpG sites shown in Figure 1 indicate that
CdLS has a distinct methylation proﬁle as compared to
controls. Of note, NIPBL transcription has only dropped
30% in those CdLS cells presenting the unique
disease-speciﬁc DNA methylation pattern in the current
Table 1. Speciﬁc histone modiﬁcation markers and repetitive genomic
sequences are enriched in chromatin regions harboring diﬀerentially
methylated CpGs in CdLS
Hyper_M Hypo_M
Histone
modiﬁcation
markers
H2A_H4R3me2 H2A_Z
H3K27me1, H3K27me2 H3K27me3
H3K36me1 H3K4me2, H3K4me3
H3K9me1, H3K9me3
H3R2me1, H3R2me2
H4K20me1, H4K20me3
H3K79me3
Repetitive
sequences
LINE repClass_Low_complexity
SINE repFamily_Low_complexity
L2
EpiGRAPH analysis was performed on 361 1-kb DNA fragments sur-
rounding diﬀerentially hyper-methylated CpGs and 563 1-kb fragments
surrounding diﬀerentially hypo-methylated CpGs in CdLS.
Hyper_M: chromatin region with diﬀerential hyper-methylation in
CdLS; Hypo_M: chromatin region with diﬀerential hypo-methylation
in CdLS.
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study (26). The hierarchial clustering also demonstrated
that the methylation proﬁle correlates to disease severity
and to the speciﬁc mutated genes: the mildly aﬀected
probands stay midway between severe probands and
controls; mildly aﬀected probands with NIPBL mutations
were clustered as a transient group between the mildly
aﬀected individuals with mutations in other genes
(SMC1A or SMC3); and the severe individuals with
NIPBL mutations suggesting a genotype–phenotype cor-
relation (Figure 1B). However, CdLS DNA methylation
proﬁle alone is not sensitive enough to serve as a diagnos-
tic tool (Supplementary Figure S5). Leave-One-Out cross
validation using P< 0.001 on 22 healthy controls and 22
severely aﬀected CdLS probands with NIPBL mutations
was conducted. Controls and probands could be roughly
separated; however, 11 samples were mis-classiﬁed after 44
rounds with a classiﬁcation accuracy of only 75%.
We next attempted to correlate the data from the three
sets of genome-wide analyses on DNA methylation, gene
expression and cohesin binding in CdLS. Venn diagram
analysis did not reveal a single gene that had signiﬁcant
alterations in all of the three biological events
(Supplementary Figure S6); therefore, no direct correl-
ation between the three dysregulated biological events
could be revealed in CdLS, indicating that additional
unknown mechanisms might be involved in the pathogen-
esis of CdLS. That there is no remarkable correlation
between gene expression and DNA methylation identiﬁed
in CdLS probably can be explained by (i) A relatively big
variation of DNA methylation level exists in healthy
controls as seen on both array and BS (Supplementary
Figure S1B and Figure 7) which adds to the diﬃculty of
identifying an unambiguously changed DNA methylation
pattern in CdLS. (ii) Global DNA methylation is a more
stable type of epigenetic modiﬁcation modulating the tran-
scriptional plasticity in the human genome than we have
realized (48). One study reporting the high-resolution
methylation states on 1.9 million CpGs on human
chromosomes 6, 20 and 22 from 12 diﬀerent tissues
failed to correlate DNA methylation with mRNA expres-
sion levels for 63% of the genes. Therefore, the author
suggested that diﬀerential promoter methylation might
have only a permissive role, such as establishing an open
chromatin conformation, for the transcription regulation.
In combination with other factors or mechanisms that
drive transcription but not alone, DNA methylation
could regulate the transcription of the cognate genes
(49). To support this argument, in our study we have
found keratin genes that are not expressed in the studied
LCLs, most promoters of the two keratin gene clusters
located on chromosome 12 and 17 are constantly under
hyper-methylation in control cells. In CdLS, uniform
methylation was found again at the two clusters but
with even higher methylation levels (Supplementary
Figure S7A and B). Keratin genes remain silent in both
control and CdLS cells with diﬀerential promoter
hyper-methylation levels, suggesting gene expression is
not solely controlled by DNA methylation. (iii) The
average global DNA methylation level in LCLs is low,
and overall methylation changes between control and
CdLS are quite subtle, making it more diﬃcult to
identify minor but signiﬁcant changes. (iv) As seen in
Drosophila, NIPBL or cohesin may regulate transcription
mainly by the association with enhancers or other remote
regulatory elements ﬁrst and only subsequently with pro-
moters. The CpG dinucleotides examined on the
Methylation27 platform in this study have minimal
coverage of the remote cis elements, which could lead to
the lack of detection of any DNA methylation alteration
on enhancers, silencers, insulators, locus control regions,
etc. We therefore propose whole-genome BS to be the next
experimental approach.
In humans, most genes are expressed from both alleles
in diploid cells; however, more and more genes are being
identiﬁed that are only expressed from a single allele.
Mammalian X inactivation, imprinting (e.g. IGF2 and
H19), and allelic exclusion (e.g. olfactory receptor genes,
immunoglobulin genes, T cell receptors, interleukins and
natural killer cell receptors) are classic examples of
monoallelic gene expression. A recent report suggests at
least 1000 autosomal human genes are subject to random
monoallelic expression (50). Regulation of this group of
genes is clearly epigenetic and the role of DNA methyla-
tion in imprinting has been well recognized, for example,
allele-speciﬁc DNA methylation has been observed for the
immunoglobulin gene and few other monoallelically ex-
pressed genes (50–52). Hence, we combined the data set
from this study with our previous genome-wide gene ex-
pression study and ChIP–chip assay to test whether diﬀer-
ential DNA methylation aﬀects monoallelic expression in
CdLS and whether it is also involved in the altered
cohesin–chromatin association in CdLS. Information on
documented human imprinted genes was obtained from
the online database ‘Catalogue of Parent of Origin
Eﬀects’ (http://igc.otago.ac.nz/Summary-table.pdf), a list
of X-linked genes with their X inactivation status and a
list of monoallelically expressed autosomal genes were
obtained from the literature (50,53). Twenty-nine im-
printed genes, 465 X-linked genes and 191 randomly
(paternal or maternal) monoallelically expressed auto-
somal genes have data available from all the three assays
(DNA methylation, expression and ChIP–chip). Fisher’s
exact tests did not reveal any correlation between diﬀer-
ential DNA methylation and the diﬀerential expression
for monoallelically expressed genes in severely aﬀected
CdLS probands with NIPBL mutations (Supplementary
Table 6). In addition, correlation between the diﬀerential
DNA methylation and altered cohesin binding (loss or
addition) at transcription start sites (TSSs), and correl-
ation between the altered cohesin binding at TSSs and
the diﬀerential gene expression for the monoallelically ex-
pressed genes were not identiﬁed either (Supplementary
Table S7). In conclusion, the current data are not able
to support an impact of CdLS-related disruption of
cohesin on monoallelic gene expression. This may be due
to the tissue or developmental stage speciﬁcity of expres-
sion of these genes.
DNA methylation state is inﬂuenced by a number of
endogenous and exogenous parameters such as gender,
age, tissue type or passage of cell cultures (54). To be
consistent, all samples for expression and methylation
studies were from Caucasians, all three genome-wide
Nucleic Acids Research, 2010, Vol. 38, No. 17 5669
assays used the same tissue type (LCLs), and the same set
of samples were used for all the studies whenever possible.
Gender was strictly matched for the diﬀerential expression
and DNA methylation analyses. Only two factors, the age
and the culture passage, could not be controlled for strin-
gently due to the limitation of resources. Most of our
CdLS probands are children and some of the healthy
controls are adults. The LCLs we have used are stock
cell lines that have been continuously collected in our
laboratory for decades. However, in one report, no detect-
able global changes in average DNA methylation levels
can be recognized between a group of 26-year-olds and
the second group of 68-year-olds (49), and, in another
report, the methylation change during prolonged passage
in culture is suggested to be insigniﬁcant (55).
At present, genome-wide information of gene expres-
sion, DNA methylation and cohesin binding in CdLS is
available from our integrative studies. The tip of the
iceberg revealed in these studies will help us to design
new assays to further understand how cohesin regulates
critical biological pathways in humans. For example, ‘6C’
could be conducted to identify epigenetic chromatin
looping structure mediated by cohesin at speciﬁc loci
that associate with a particular gene transcription
pattern. Allele-speciﬁc DNA methylation cannot be
studied on the current array platform but could be
possible if combined with the SNP information. The
combined data will help us to illustrate NIPBL and
cohesin’s role in monoallelic expression in the human
genome, knowledge of which is currently lacking. ChIP–
chip or ChIP–Seq studies to identify speciﬁc histone
modiﬁcations in CdLS are also a needed next step to
understand how chromatin structure is involved in
human developmental disorders. Finally, animal models
with complete or partial NIPBL or cohesin knockdown
may help us to interpret cohesin-dependent cellular func-
tions in vivo.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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